Albert B. Chandler Medical Center, University of Kentucky

Summary

Albert B. Chandler Medical Center, University of Kentucky is a medical facility located in Lexington, Kentucky. This center is recognized for care of Lung Cancer, Ovarian Cancer, Leukemia, Head and Neck Cancers, Brain Tumor and other specialties. Albert B. Chandler Medical Center, University of Kentucky is involved with conducting 241 clinical trials across 276 conditions. There are 7 research doctors associated with this hospital, such as Daniel Lee, MD, Francis Farhadi, MD, PhD, Frederick R. Ueland, and Sharoon Qaiser.

Top PIs

Clinical Trials running at Albert B. Chandler Medical Center, University of Kentucky

Lung Cancer

Prostate Cancer

Cancer

Migraine

Spinal Cord Injury

Multiple Sclerosis

Non-Small Cell Lung Cancer

Diffuse Large B-Cell Lymphoma

Non-Hodgkin's Lymphoma

Ovarian Cancer

LY3537982 + Immunotherapy/Chemotherapy

for Non-Small Cell Lung Cancer

This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.

Recruiting

1 award

Phase 3

14 criteria

BNT116 + Standard Therapy

for Non-Small Cell Lung Cancer

This first-in-human (FIH) trial for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab, docetaxel, carboplatin, paclitaxel, BNT316 (an anti-cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\] antibody), an anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor, an anti-human epidermal growth factor receptor 3 (HER3) antibody conjugated to a topoisomerase I inhibitor or a bispecific antibody for programmed death ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A) in participants with non-small cell lung cancer (NSCLC). The trial will comprise of several cohorts for dose confirmation in monotherapy as well as in combinations of BNT116 as mentioned above. The trial will enroll participants with NSCLC in advanced or metastatic stage in Cohorts 1 to 4 and Cohorts 7 to 10, unresectable NSCLC Stage III in Cohorts 5 and 11, and resectable NSCLC of Stage II and III in Cohort 6.

Recruiting

1 award

Phase 1

15 criteria

Investigational Agents

for Lung Cancer

Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the lungs. Metastatic means the cancer has spread to other parts of the body. Standard treatment (usual treatment) for metastatic squamous NSCLC is immunotherapy with or without chemotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. However, standard treatment may not work or may stop working to treat metastatic squamous NSCLC. Researchers want to learn if study treatments that are antibody drug conjugates (ADCs) can treat metastatic squamous NSCLC that did not respond (get smaller or go away) to standard treatment. An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goals of this study are to learn about: * The cancer response to the study treatments compared to chemotherapy * The safety of the study treatments and if people tolerate them This study is one of the substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

Recruiting

1 award

Phase 2

3 criteria